nuclear medicine cooperation

Lutetium-177, The Increasing Production Of A Promising Radioisotope

Lutetium-177, The Increasing Production Of A Promising Radioisotope Lutetium-177 (Lu-177) is considered to be one of the most promising radioisotopes. Radiopharmaceuticals based on Lu-177 have already demonstrated excellent therapeutic performance in several applications, as prostate cancer and gastroenteropancreatic neuroendocrine tumors treatment. Thanks to its efficient performances and results, the demand for Lu-177 is growing. Several…

NRG delivers 10 patient doses of Lutetium-177

NRG delivers 10 patient doses of Lutetium-177 Last week, NRG has delivered lutetium for the first time to an academic hospital and two pharmaceutical parties this month. Sander de Groot, program manager medical isotopes at NRG: “This isotope offers a great perspective for the effective treatment of various cancer indications and with limited side effects.…

SCK CEN And Quirem Medical Start Producing Ho-166 Microspheres At BR2 Reactor

SCK CEN And Quirem Medical Start Producing Ho-166 Microspheres At BR2 Reactor SCK CEN and Quirem Medical announce the first production of holmium-166 microspheres for patient use at the BR2 reactor in Mol, Belgium. A first clinical QuiremSpheres® patient procedure took place with radioactive holmium-166 microspheres, an innovative product for treating liver cancer patients. QuiremSpheres is…

nuclear medicine cooperation

Mo-99 Ready To Be Produced At Darlington NPP

Mo-99 Ready To Be Produced At Darlington NPP The Darlington Nuclear Power Plant, located in Canada and operated by Ontario Power Generation (OPG), is now ready to produce life-saving Molybdenum-99 (Mo-99) isotopes, Laurentis Energy Partners and BWXT Medical Ltd announced last week. Thanks to the installation and initial commissioning of an innovative isotope system made…